Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in
Phase III Pivotal Trial as Compared to Neostigmine
OSS, The Netherlands, June 11, 2007 /PRNewswire/ --
Sugammadex -the novel selective relaxant binding agent (SRBA) being developedby Organon, the human healthcare business unit of Akzo Nobel -demonstrated in a Phase III pivotal trial a 9-12 times fasterreversal of neuromuscular blockade as compared to neostigmine,without evidence of post operative residual curarization (PORC) orre-occurre...
Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in
Phase III Pivotal Trial Compared to Neostigmine
OSS, the Netherlands, June 11, 2007-
Sugammadex - the novelselective relaxant binding agent (SRBA) being developed by Organon,the human healthcare business unit of Akzo Nobel - demonstrated ina Phase III pivotal trial a 9-12 times faster reversal ofneuromuscular blockade as compared to neostigmine, without evidenceof post operative residual curarization (PORC) or re-occurrence ofmuscle relax...